Following AHSCT, both Th17-related cytokines (IL-17, IL-1β, IL-21 and IL-23) and Th1-related cytokines (IFNγ and IL-12p70) were significantly reduced in MS patients, and this change was sustained up to 24 months post-AHSCT. The gene discussed is IL17A; the disease is myeloid sarcoma.